Calcitonin Salmon

Summary

Calcitonin Salmon (CHEMBL3989767) is an approved protein bone density conservation agent (ATC H05BA01); indicated across 8 conditions including postmenopausal osteoporosis and bone paget disease.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Protein
• ATC class: H05BA01
• Indications: 8 conditions
• Clinical trials: 12
• Chemistry: 3431.9 Da · C145H240N44O48S2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL3989767
Name	Calcitonin Salmon
Type	Protein
Max phase	4
FDA approved	no
PubChem CID	16133812
ChEBI	CHEBI:3306
ATC	H05BA01
Molecular formula	C145H240N44O48S2
Molecular weight	3431.9
InChIKey	BBBFJLBPOGFECG-VJVYQDLKSA-N

SMILES: C[C@H]([C@H]1C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CO)CC(C)C)CC(=O)N)CO)N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC2=CNC=N2)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC3=CC=C(C=C3)O)C(=O)N4CCC[C@H]4C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N5CCC[C@H]5C(=O)N)O

IUPAC name: (4S)-4-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[2-[[(2S)-2-[[(2S)-2-[[(4R,7S,10S,13S,16S,19S,22R)-22-amino-16-(2-amino-2-oxoethyl)-7-[(1R)-1-hydroxyethyl]-10,19-bis(hydroxymethyl)-13-(2-methylpropyl)-6,9,12,15,18,21-hexaoxo-1,2-dithia-5,8,11,14,17,20-hexazacyclotricosane-4-carbonyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]hexanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S,3R)-1-[[(2S)-1-[(2S)-2-[[(2S)-1-[[(2S,3R)-1-[[(2S)-4-amino-1-[[(2S,3R)-1-[[2-[[(2S)-1-[[2-[[(2S,3R)-1-[(2S)-2-carbamoylpyrrolidin-1-yl]-3-hydroxy-1-oxobutan-2-yl]amino]-2-oxoethyl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-oxopentanoic acid

ChEBI definition: A 32-membered heterodetic cyclic peptide comprising the sequence Cys-Ser-Asn-Leu-Ser-Thr-Cys-Val-Leu-Gly-Lys-Leu-Ser-Gln-Glu-Leu-His-Lys-Leu-Gln-Thr-Tyr-Pro-Arg-Thr-Asn-Thr-Gly-Ser-Gly-Thr-Pro-NH2 cyclised by a disulfide bridge between the two Cys residues at positions 1 and 7.

Pharmacological roles (ChEBI): bone density conservation agent.

Other ChEBI roles (chemical / environmental): metabolite.

Also known as: Calcimar, Calcitonin (salmon synthetic), Calcitonin salmon, Calcitonin salmon recombinant, Calcitonin-salmon, Forcaltonin, Fortical, Miacalcin, Recombinant salmon calcitonin, Scalcitonin, CALCITONIN SALMON, CALCITONINE

Patent coverage: 274 distinct patent families (666 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 619 (93%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 5 (assay-derived). Sample: Calcitonin receptor, Calcitonin-gene-related peptide receptor, CALCRL/RAMP1, Amylin receptor AMY3; CALCR/RAMP3, Amylin receptor AMY3; CALCR/RAMP3, Calcitonin receptor.

Bioactivity

ChEMBL activities: 6 potent at pChembl ≥ 5 of 6 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
RAMP3	10.87	EC50	0.01	nM	CHEMBL_ACT_25914952
P32214	10.55	IC50	0.03	nM	CHEMBL_ACT_25914664
P32214	10.52	IC50	0.03	nM	CHEMBL_ACT_25914682
CALCR	10.18	IC50	0.07	nM	CHEMBL_ACT_25914628
RAMP3	10.05	IC50	0.09	nM	CHEMBL_ACT_25914610
RAMP1	6.41	EC50	389.1	nM	CHEMBL_ACT_25914956

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

8 indications (5 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
postmenopausal osteoporosis	4	MONDO:0008159	EFO:0003854
bone Paget disease	4	MONDO:0005382	EFO:0004261
hypercalcemia disease	4	MONDO:0001566	HP:0003072
parathyroid gland disorder	4	MONDO:0001223	EFO:0005754
bone resorption disease	4	MONDO:0000837	MONDO:0000837
osteoporosis	3	MONDO:0005298	EFO:0003882

2 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 12.

Phase distribution

Phase	Trials
PHASE3	5
PHASE1	4
PHASE4	2
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00239889	PHASE4	COMPLETED	Efficacy and Safety of Salmon Calcitonin Nasal Spray in Improving Muscle Strength and Reducing Pain After Forearm Fracture in Postmenopausal Women
NCT00754884	PHASE4	WITHDRAWN	Calcitonin in the Treatment of Fibromyalgia
NCT00372099	PHASE3	COMPLETED	Bone Microstructure in Nasal Salmon Calcitonin Treated Postmenopausal Women
NCT00414973	PHASE3	COMPLETED	A Study for Patients With Osteoporosis
NCT00542984	PHASE3	COMPLETED	Comparison Medications in the Treatment of Postmenopausal Women With Osteoporosis
NCT00543023	PHASE3	COMPLETED	A Study of the Treatment of Postmenopausal Women With Osteoporosis
NCT00704847	PHASE3	TERMINATED	Efficacy and Safety of Oral Salmon Calcitonin in Patients With Knee Osteoarthritis (OA 2 Study)
NCT00376311	PHASE2	TERMINATED	Effects of Oral Salmon Calcitonin in Human Osteoarthritis
NCT00395395	PHASE1	COMPLETED	Effects of Water and Food Intake on the Pharmacokinetics and Pharmacodynamics of Oral Salmon Calcitonin in Healthy Postmenopausal Women
NCT00411125	PHASE1	COMPLETED	Pharmacokinetics and Pharmacodynamics Study of Oral Salmon Calcitonin in Healthy Postmenopausal Women
NCT00486317	PHASE1	COMPLETED	Pharmacokinetics/Pharmacodynamics of Oral Salmon Calcitonin in Patients With Osteoarthritis
NCT00486369	PHASE1	COMPLETED	SMC021A - Absorption, Efficacy and Tolerance in Patients With Osteoarthritis. A Placebo-Controlled 14-Days Study

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).